Nazarius S Lamango Selected Research

ras Proteins

11/2021	Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors.
1/2021	Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling.
1/2019	Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells.
1/2016	Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nazarius S Lamango Research Topics

Disease

16	Neoplasms (Cancer) 02/2024 - 01/2009
4	Parkinson Disease (Parkinson's Disease) 03/2006 - 12/2003
3	Breast Neoplasms (Breast Cancer) 02/2024 - 12/2020
3	Lung Neoplasms (Lung Cancer) 01/2019 - 01/2014
2	Triple Negative Breast Neoplasms 12/2022 - 12/2020
2	Neoplasm Metastasis (Metastasis) 12/2020 - 05/2017
2	Schizophrenia (Dementia Praecox) 12/2020 - 06/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2018 - 05/2017
2	Prostatic Neoplasms (Prostate Cancer) 01/2017 - 01/2014
2	Adenocarcinoma 01/2016 - 06/2014
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2016 - 06/2014
1	Bipolar Disorder (Manic Depressive Psychosis) 12/2020
1	Mood Disorders (Mood Disorder) 12/2020
1	Retinal Neovascularization 10/2016
1	Catalepsy 09/2014
1	Erectile Dysfunction 06/2014
1	Neuroblastoma 04/2014
1	Colorectal Neoplasms (Colorectal Cancer) 01/2013
1	Carcinogenesis 11/2011
1	Pheochromocytoma 03/2007
1	Retinal Degeneration 01/2005
1	Parkinsonian Disorders (Parkinsonism) 01/2005

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2003
9	AmidesIBA 02/2024 - 01/2016
5	EsterasesIBA 01/2021 - 01/2013
4	GTP-Binding Proteins (G-Protein)IBA 02/2024 - 06/2014
4	ras ProteinsIBA 11/2021 - 01/2016
4	EnzymesIBA 01/2013 - 01/2005
3	Monomeric GTP-Binding ProteinsIBA 01/2023 - 05/2017
3	Haloperidol (Haldol)FDA LinkGeneric 12/2022 - 09/2014
3	S-Adenosylmethionine (Ademetionine)IBA 07/2004 - 12/2003
2	Actins (F Actin)IBA 05/2017 - 01/2017
2	CaspasesIBA 01/2017 - 03/2007
2	Biomarkers (Surrogate Marker)IBA 06/2014 - 01/2014
1	Phosphotransferases (Kinase)IBA 02/2024
1	OximesIBA 12/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021
1	Estrogen ReceptorsIBA 12/2020
1	4- (4- (4- chlorophenyl)- 1,4- diazepan- 1- yl)- 1- (4- fluorophenyl)butan- 1- oneIBA 12/2020
1	Epidermal Growth Factor (EGF)IBA 12/2020
1	Antipsychotic Agents (Antipsychotics)IBA 12/2020
1	Progesterone Receptors (Progesterone Receptor)IBA 12/2020
1	Caspase 3 (Caspase-3)IBA 01/2017
1	Antineoplastic Agents (Antineoplastics)IBA 01/2016
1	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 09/2014
1	farnesylthiosalicylic acidIBA 06/2014
1	LigandsIBA 06/2014
1	acetyl methyl tetramethyl tetralinIBA 04/2014
1	galaxolideIBA 04/2014
1	AndrogensIBA 01/2014
1	CurcuminIBA 01/2013
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2011
1	ProstaglandinsIBA 11/2011
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 11/2011
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 11/2011
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 11/2011
1	Oxidopamine (6 Hydroxydopamine)IBA 03/2007
1	ParaquatIBA 03/2006
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 03/2006
1	Parathion (Ethyl Parathion)IBA 01/2005
1	Paraoxon (E600)IBA 01/2005
1	prenylcysteineIBA 12/2003

Therapy/Procedure

7	Therapeutics 02/2024 - 06/2014
1	Castration 01/2017
1	Chemoprevention 01/2013